**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: 12/25/1965
* Admission Date: March 10, 2023
* Discharge Date: March 20, 2023

**Clinical Summary:**

John Doe, a 57-year-old male, was admitted to the endocrinology unit on March 10, 2023, with symptoms of increased thirst and urination, fatigue, and blurred vision. He had a history of hypertension and hyperlipidemia. Upon admission, his fasting plasma glucose (FPG) level was 220 mg/dL (12.2 mmol/L), and his glycosylated hemoglobin (HbA1C) was 8.5%. He underwent an oral glucose tolerance test (OGTT), which confirmed the diagnosis of type 2 diabetes.

**Diagnostic Workup:**

* Laboratory tests: FPG, HbA1C, OGTT, and urinalysis
* Physical examination: Patient was observed to have bilateral pedal edema and a mildly pale optic disc
* Imaging studies: None performed

**Treatment and Management:**

* Diet: Individualized dietary recommendations were provided, focusing on whole foods, high-quality carbohydrates, and adjustments for comorbid conditions
* Exercise: Encouraged to engage in at least 150 minutes of moderate-intensity aerobic exercise per week, with adjustments for hypoglycemia risk
* Medications:
	+ Metformin 500 mg twice daily, adjusted to achieve a target HbA1C level of <7.0%
	+ Semaglutide 2.4 mg subcutaneously once weekly for weight loss and glycemic control
* Patient education:
	+ Provided detailed information on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and diabetic complications
	+ Educated on adjusting insulin doses based on blood glucose levels and carbohydrate intake
	+ Reinforced the importance of regular professional podiatric care and vaccinations against Streptococcus pneumoniae, influenza virus, hepatitis B, varicella, and SARS-CoV-2

**Complications and Prognosis:**

* No significant complications were noted during hospitalization
* Patient was advised to monitor for signs and symptoms of diabetic complications, including nephropathy, retinopathy, and neuropathy

**Discharge Instructions:**

* Continue metformin 500 mg twice daily and semaglutide 2.4 mg subcutaneously once weekly
* Monitor blood glucose levels regularly and adjust medications as needed
* Engage in regular physical activity, including aerobic and resistance exercises
* Adjust insulin doses based on blood glucose levels and carbohydrate intake
* Attend regular follow-up appointments with the endocrinologist and primary care physician

**Follow-up Care:**

* Scheduled follow-up appointment with the endocrinologist in 2 weeks
* Scheduled follow-up appointment with the primary care physician in 1 month

**Additional Recommendations:**

* Consider referral to a registered dietitian for personalized dietary counseling
* Consider referral to a physical therapist for exercise guidance and monitoring
* Consider referral to a podiatrist for regular professional care

**Signature:**

I, [Your Name], MD, hereby certify that the above information accurately reflects the patient's medical history, diagnosis, treatment, and discharge instructions.